REDWOOD CITY, Calif.,
Nov. 8, 2016 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
moderate-to-severe acute pain, today announced that senior
management will be participating at the Global Mizuho Investor
Conference, the Jefferies London Healthcare Conference and Piper
Jaffray Healthcare Conference. Details of the events are as
follows:
Global Mizuho Investor Conference
Date: Monday, November 14th
Location: Omni Berkshire New York
Jefferies London Healthcare Conference
Date:
Wednesday, November 16th
Location: Waldorf Hilton London
Presentation Time: 5:20 pm GMT
(9:20 am PT)
Piper Jaffray Healthcare Conference
Date: Tuesday, November 29th
Location: Lotte New York Palace Hotel
Presentation Time: 12:00 pm ET
(9:00 am PT)
Presentations from the Jefferies and
Piper Jaffray conferences will be webcast live and can be
accessed through the Investors page at www.acelrx.com. For those
not available to listen to the live broadcast, a replay will be
archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of moderate-to-severe acute pain. The Company's
late-stage pipeline includes ARX-04 (sufentanil sublingual tablet,
30 mcg), designed for the treatment of moderate-to-severe acute
pain in medically supervised settings; and Zalviso®
(sufentanil sublingual tablet system), designed for the management
of moderate-to-severe acute pain in adult patients in the hospital
setting. Zalviso delivers 15 mcg sufentanil sublingually through a
non-invasive delivery route via a pre-programmed,
patient-controlled analgesia device. Zalviso is approved in the EU
as well as Norway, Iceland, and Liechtenstein and is investigational and in
late-stage development in the U.S. Grunenthal Group holds the
rights for Zalviso in Europe and
Australia, while AcelRx retains
all other world-wide rights.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Forward-Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to the process and timing of anticipated future
development of AcelRx's product candidates, ARX-04 (sufentanil
sublingual tablet, 30 mcg) and Zalviso® (sufentanil sublingual
tablet system), including the ARX-04 clinical trial results;
anticipated submission of the New Drug Application, or NDA, for
ARX-04 to the U.S. Food and Drug Administration, or FDA; AcelRx's
pathway forward towards gaining approval of Zalviso in the U.S.;
and the therapeutic and commercial potential of AcelRx's product
candidates, including potential market opportunities for ARX-04 and
Zalviso. These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals' actual
results and timing of events could differ materially from those
anticipated in such forward-looking statements, and as a result of
these risks and uncertainties, which include, without limitation,
risks related to AcelRx Pharmaceuticals' ARX-04 development program
the uncertain clinical development process; the success, cost and
timing of all development activities and clinical trials; and other
risks detailed in the "Risk Factors" and elsewhere in AcelRx's U.S.
Securities and Exchange Commission filings and reports, including
its Quarterly Report on Form 10-Q filed with the SEC on
November 2, 2016. AcelRx undertakes
no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or changes in its expectations.
![AcelRx logo. AcelRx logo.](http://photos.prnewswire.com/prnvar/20130226/MM67303LOGO)
Logo -
http://photos.prnewswire.com/prnh/20130226/MM67303LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-at-three-upcoming-investor-events-in-november-300358788.html
SOURCE AcelRx Pharmaceuticals, Inc.